SEBULSKY ALAN purchased $474K of PBLS (indirect holdings)
SEBULSKY ALAN purchased 17,500 indirectly-held shares of Parabilis Medicines, Inc. (PBLS) at an average of $27.06 ($26.00–$27.67, $0.47M total) across 3 trades over 2026-06-12 to 2026-06-15.
How this was made
The 30-second read
Why it matters
The newest concrete fact is the director’s open-market purchase totaling ~$473.5K across three trades, with holdings rising to 30,000 shares.
Market read
Traders may treat the disclosure as a small sentiment input, but it lacks operational or financial catalysts in the text.
What to watch
The filing doesn’t state rationale, whether the director already held shares, or whether there are concurrent corporate events (financing, trial readouts) that would better explain price action.
Background
The article is an SEC Form 4 insider transaction disclosure for Parabilis Medicines, Inc. (PBLS).
Ticker impact
SEC Form 4 shows director Alan Sebulsky bought $473.5K of PBLS shares in open-market trades (17,500 shares) June 12–15.
Near-term: limited upside bias; any move likely fades unless followed by operational news.
This is a routine Form 4 disclosure with no 10b5-1 plan and no accompanying company-specific fundamental update in the text.
Market effects
Minimal; single-company insider transaction without sector-wide signal.
None indicated.
None indicated.
Counterpoint
Insider buys can be driven by diversification, liquidity needs, or non-informational motives; without a 10b5-1 plan, it still doesn’t confirm bullish fundamentals.
Key entities
- issuerParabilis Medicines, Inc.
PBLS; subject of the Form 4 insider transaction disclosure.
- insiderSEBULSKY ALAN
Director who purchased PBLS shares in open-market trades June 12–15.